110 studies found for:    Open Studies | "Hemophilia A"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Hemophilia A"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Conditions: Hemophilia A;   Severe Hemophilia A
Intervention: Biological: rVIII‑SingleChain
2 Not yet recruiting Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A
Condition: Hemophilia A
Intervention: Drug: ADVATE
3 Not yet recruiting Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A
Condition: Hemophilia A
Intervention: Drug: Recombinant Human Coagulation Factor VIII for injection
4 Recruiting PK Driven Prophylaxis for Hemophilia A
Condition: Hemophilia A
Intervention: Device: MyPKFiT
5 Recruiting Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
Condition: Hemophilia A
Intervention: Drug: Plasma-derived FVIII/VWF concentrate
6 Recruiting Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients
Conditions: Hemophilia A;   Factor VIII
Intervention: Drug: Recombinant VIII factor
7 Recruiting Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Condition: Severe Hemophilia A
Intervention: Drug: Alphanate SD/HT
8 Not yet recruiting Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors
Condition: Hemophilia A With Inhibitor
Intervention:
9 Recruiting Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
Condition: Haemophilia A
Intervention: Biological: Optivate 500IU
10 Recruiting A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
Condition: Hemophilia A
Intervention: Drug: Emicizumab
11 Recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: rFVIIIFc
12 Recruiting Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."
Condition: Hemophilia A
Intervention: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
13 Recruiting Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens
Condition: Severe Haemophilia A
Intervention: Drug: ADVATE [Antihemophilic Factor (Recombinant)]
14 Recruiting ADVATE Hemophilia A Outcome Database (AHEAD)
Condition: Hemophilia A
Intervention: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
15 Recruiting Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
16 Recruiting National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A
Condition: Hemophilia A
Intervention: Behavioral: Educational Package
17 Unknown  Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: GreenGene™ F
18 Recruiting Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Condition: Hemophilia A
Intervention: Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
19 Unknown  Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Condition: Hemophilia A
Interventions: Biological: GreenGene™ F and an approved recombinant Factor VIII product;   Biological: GreenGene™ F
20 Recruiting A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: MOD-5014

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years